We conducted a retrospective study to assess the effects of infl iximab, a chimeric monoclonal antibody, on hearing in patients with autoimmune sensorineural hearing loss who had previously not responded to steroid therapy and/ or treatment with other immunosuppressive drugs such as methotrexate and cyclophosphamide. We reviewed the records of 8 such patients. Our objective measures of outcome were pure-tone averages at 500, 1,000, 2,000, and 3,000 Hz and speech discrimination scores. At the completion of treatment, no patient exhibited a positive response to infl iximab therapy by objective measurements, and only 1 patient (12.5%) reported subjective improvement.
Introduction
Autoimmune sensorineural hearing loss (AISNHL) was fi rst described by McCabe in 1979. 1 It is usually described as a slowly progressive, asymmetric hearing loss. AISNHL can persist over a period of weeks to months, with or without tinnitus and vestibular symptoms. Its course is highly variable. Although its classic presentation is one of slow progression, it may also present as sudden deafness or as a sensorineural hearing loss of any pattern, with either tinnitus alone or dizziness alone. The impact of AISNHL can be refl ected in both pure-tone average (PTA) and speech discrimination score (SDS).
Clinical studies [2] [3] [4] and research [5] [6] [7] [8] [9] [10] [11] are beginning to provide additional information about the presentation, diagnosis, and management of this complex condition. There is no single diagnostic test for AISNHL; the diagnosis is generally made on the basis of the history, clinical fi ndings, the patient's response to immunosuppressive therapy, and an immunologic evaluation of the patient's inner ear antigen. Several diagnostic tests are available, including the lymphocyte transformation assay, the Western blot analysis for inner ear antibodies, the test for protein zero, and supporting-cell immunofl uorescence testing. Of these tests, the Western blot assay for cochlear antibodies and the test for protein zero are used most often to help establish the diagnosis.
Patients with AISNHL confi rmed by a positive Western blot test usually respond to medications used to treat other autoimmune conditions. For patients with suspected AISNHL, most authors agree that a steroid trial is warranted. However, the role of immunosuppressive/cytotoxic therapy has not been fully clarifi ed. At the practice of the senior author (R.T.S.), the routine protocol (barring medical contraindications) is to start patients on a steroid. If they do not respond or if they become steroid-dependent, we switch them to methotrexate. If they still do not respond, the methotrexate is discontinued and cyclophosphamide is substituted.
In this article, we describe our investigation of the use of the cytotoxic agent infl iximab in patients with treatment-refractory AISNHL
Patients and methods
Our study population was made up of 8 patients in the senior author's practice who had been diagnosed with AISNHL and who had not responded to steroid therapy, methotrexate, and/or cyclophosphamide. The study group included 4 men and 4 women, aged 41 to 65 years (mean: 57.5).
In addition to confi rmed AISNHL in all 8 patients, tinnitus had been present in 2 patients, vertigo in 3, and Ménière syndrome in 2. Two patients had tested positive for the 68-kd bovine inner ear antigen on Western blot analysis, and 4 had tested positive for protein zero.
Infl iximab treatment. Following the failure of the initial standard drug regimen, the 8 patients were treated with infl iximab by another of the authors (R.R.). These patients had received between 320 and 600 mg of infl iximab intravenously at 4-to 12-week intervals. The duration of treatment, which ranged from 13 to 170 weeks (table 1), was determined by audiologic response.
The potential side effects of infl iximab had been reviewed with all patients prior to the start of therapy. All patients underwent periodic complete blood cell count measurements and liver and renal function testing during infl iximab treatment.
Objective measures of outcome. Each patient's initial audiogram was used as the baseline from which any improvement or decline in PTA or SDS could be measured. In addition to baseline, air-conduction (250 to 8,000 Hz) and bone-conduction thresholds (250 to 4,000 Hz) were measured monthly during treatment and for the fi rst year after the completion of treatment and then every 3 months thereafter. The SDS was assessed at the same times. The PTA at 500, 1,000, 2,000, and 3,000 Hz was calculated for all patients prior to therapy, during any response period, and at the completion of therapy.
We also assessed subjective improvement in hearing and alleviation of tinnitus and vertigo, and we analyzed typing data for human leukocyte antigen (HLA) -B, -C, and -DR.
Three criteria were used to quantify each patient's response to drug treatment:
Criterion I: An improvement of 10 dB or more in at least three frequencies between 250 and 8,000 Hz Criterion II: An improvement of 15 dB or more in at least two frequencies between 250 and 8,000 Hz Criterion III: An improvement of at least 20% in SDS
Results
Of the 8 patients, none experienced an objective response to infl iximab, although 1 patient reported a subjective hearing improvement and was still on infl iximab at study's end (patient 1). In the other 7 patients, infl iximab was stopped when patients did not respond after 3 to 14 infusions.
Typing data for HLA were available for analysis for the entire population. Of the 8 patients, 3 were positive for HLA-B35, 2 were positive for HLA-CW4, 3 were positive for HLA-CW7, and 1 was positive for HLA-DR4 (table 2) .
Discussion
AISNHL is most likely an immune-mediated condition, although there is no direct evidence of its autoimmune etiology. 12 Possible etiologic factors include cochlear or vestibular membrane ruptures, viral or bacterial inner ear infections, vascular compromise, metabolic disorders, and cochlear infl ammation. [13] [14] [15] [16] [17] [18] Further research is needed to determine the pathophysiologic mechanisms of AISNHL.
Because of the uncertainty over the cause of AISNHL, otologists have tried many treatment regimens with various results. Treatment of patients in the acute stage of AISNHL usually includes the use of corticosteroids, which is the only validated treatment option. 19 However, many patients relapse as corticosteroids are tapered. Other immunosuppressive regimens for patients who cannot be weaned off corticosteroids or whose disease becomes refractory to treatment have proven to be diffi cult to develop. Steroid-sparing agents such as methotrexate and cyclophosphamide are used, but success has been mixed. For example, in a randomized, double-blind trial of 67 patients, Harris et al found that methotrexate was no more effective than placebo in maintaining hearing 20 Over time, attention turned to two tumor necrosis factor-alpha (TNF-α) antagonists: infliximab and etanercept, TNF-α is a cytokine and a key part of the autoimmune reaction. Infl iximab is a chimeric monoclonal antibody that binds to both the soluble and transmembrane forms of TNF-α and neutralizes their biologic activity. Infl iximab differs from etanercept in that it neutralizes receptor-bound TNF-α. 21 Van Wijk et al conducted a preliminary study of 9 patients with AISNHL who were treated with transtympanic infl iximab and found the results encouraging. 22 On the other hand, Matteson et al conducted an open-label trial of etanercept in 23 patients with features of AISNHL and Ménière disease and found that the drug was safe but not particularly effective. 23 In our retrospective review of 8 cases, infl iximab was not effective, as no patient experienced an objective improvement and only 1 patient (12.5%) reported a subjective benefi t. However, all of the patients in our study had been selected for infl iximab treatment because their AISNHL was already refractory to all recommended treatments, including steroids, methotrexate, and/or cyclophosphamide. Thus, perhaps the true effi cacy of infl iximab is still unclear; we have found no controlled studies that have investigated the use of infl iximab as the primary treatment for AISNHL, although there have been several reports on its use for various conditions in which hearing was discussed. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] There have also been a few interesting reports suggesting the value of intratympanic administration of infl iximab. [40] [41] [42] To better evaluate infl iximab as a treatment option for AISNHL, a large, double-blind, placebo-controlled study is needed.
Finally, in studying the association between AISNHL and HLA types, Bowman and Nelson found that AISNHL was associated with the presence of HLA-B35, -CW4, and -CW7 and the absence of HLA-DR4. 43 Our fi ndings were consistent with theirs only with respect to the absence of HLA-DR4; fewer than half our patients tested positive for HLA-B35, -CW4, and -CW7. This discrepancy is most likely attributable to the small number of patients in our study. and the cyanoacrylate bolus was mobilized and removed from the nose with minimal trauma to the mucosa. The patient was subsequently advised to douche the nose with saline and to continue using his nasal steroid medication. Follow-up demonstrated no long-term sequelae.
Because cyanoacrylate injuries to otolaryngologic structures are rare, there is a paucity of information in the literature to guide the management of these unusual cases. Cyanoacrylate in the nasal passages has the potential to cause respiratory embarrassment. The nature of the substance allows it to form a cast that conforms to the shape of the airway and adheres adjacent mucosal surfaces to each other. If there are any suspicions that cyanoacrylate fragments have been inhaled, a chest x-ray and bronchoscopy may be indicated. 8 Given the success of saline swabs 8 and margarine lubrication 9 in the removal of cyanoacrylate from the oral mucosa, we could have implemented a similar technique in our case. However, our options were limited by our inability to (1) assess the posterior extent of the injury and (2) gain access to the surface area of the involved nasal mucosa. Therefore, we chose the course we did. Based on our experience and our review of literature, we now propose an algorithm that may help clinicians in making informed decisions regarding the management of a nasal cyanoacrylate injury (fi gure 2).
